#USA #Prague #BTL #EXOLASE ONE® #Erbium Laser

BTL Unveils EXOLASE ONE®: A New Era in Aesthetic Laser Treatments

In a historic announcement, BTL, a global leader in energy-based medical technologies, revealed the launch of its latest innovation, EXOLASE ONE®. This breakthrough product is the world’s very first application of Fused Erbium Laser technology in medical practice, indicating a new chapter in the aesthetic industry. Manufacturing is conducted in BTL's cutting-edge European facility, showcasing their commitment to excellence.

A Major Leap in Technology

EXOLASE ONE® utilizes a patented technology that integrates multiple wavelengths into a single laser beam. This capability transforms the standard for facial rejuvenation, allowing medical professionals to target the same area simultaneously and providing a novel interaction between the laser and tissue. Traditional facial rejuvenation methods often require multiple systems—both ablative and non-ablative. However, this innovation offers a streamlined procedure that is markedly efficient, taking less than 10 minutes to treat the entire face while delivering superior clinical results.

Dr. Reha Yavuzer, a leading clinical researcher on this platform, emphasized the significant impact of this technology: "What typically requires several systems can now be accomplished in one simple procedure. The results are exceptional, offering a revolutionary experience for our patients." This shared sentiment is echoed by the CEO of BTL, Tomas Schwarz, who remarked, "From our inception, we understood that only a truly disruptive technology would enable us to establish a powerful laser brand. Feedback from pioneering clinical centers worldwide indicates that EXOLASE ONE® represents precisely that kind of advancement."

Launch and Future of EXOLASE ONE®

Having undergone a selective early-access program for key opinion leaders, EXOLASE ONE® is set for a global release in 2027. Its initial focus will lie in aesthetic medicine and dermatology, marking a vital expansion for BTL's new dedicated laser division. This venture now becomes the sixth primary division for the company, supplementing existing operations in aesthetics, mental well-being, rehabilitation, cardiology, and robotics.

BTL’s journey began in 1993, and over the years, it has emerged as one of the leading manufacturers of medical and aesthetic equipment, employing over 5,000 people across more than 90 countries. Their dedication to cutting-edge technology has led to revolutionary solutions in non-invasive body shaping, skin tightening, facial rejuvenation, mental health, rehabilitation, and cardiology. Some of their renowned brands include EMSCULPT NEO®, EMFACE®, EMSELLA®, and EXOMIND®.

As the landscape of aesthetic treatments evolves, technologies like EXOLASE ONE® symbolize the future of patient-focused care, bringing significant advancements that promise to reshape the field. Through ongoing investment in research and development, BTL continues to push boundaries, paving the way for innovative solutions that enhance both the efficiency of treatments and the overall patient experience. For more information about this groundbreaking laser technology, you can visit www.exolaseone.com or www.btlaesthetics.com.